Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Meetings With Biosimilar Sponsors Aim To Make 351(k) Pathway OK

Dec 16 2011

• By Derrick Gingery

Related Content

Biosimilars Pathway Dilemma: When Should Sponsors Pick (k) Before (a)?

May 23 2011

FDA “Busy” With Biosimilars; Sponsors Already In Pre-IND Meetings

May 16 2011

"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

Feb 14 2011

Biosimilar User Fee Program Stresses FDA/Sponsor Meetings Early And Often

Dec 12 2011

ANDA User Fees Will Fund Public Relations-focused Studies On Palatability Of Generics

Dec 12 2011

Waxman Says Biosimilar Pathway Will Push Applicants To BLA

Nov 22 2010

Additional Topics

United States Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window